Streptozotocin

SKU: orb1308404

Description

Streptozotocin is a GLUT2-transported antibiotic that selectively induces pancreatic β-cell apoptosis via DNA alkylation. It is extensively used to generate experimental models of diabetes in vivo and to study β-cell toxicity in vitro. Due to its instability, fresh preparation in solution is required.

Research Area

Cell Biology, Infectious Disease & Virology, Molecular Biology

Key Properties

• CAS Number: 18883-66-4
• MW: 265.22
• Purity: >99.99% (May vary between batches)
• Formula: C₈H₁₅N₃O₇
• SMILES: [C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)(NC(N(N=O)C)=O)C=O
• Target: DNA/RNA Synthesis,DNA Alkylator/Crosslinker,Antibiotic,Antibacterial,DNA Alkylation,Autophagy
• Solubility: H2O:113.3 mg/mL (427.19 mM);DMSO:16.67 mg/mL (62.85 mM)

Bioactivity

• Target IC50:
  DNA methylating (C1498 cells):1024 μg/mL|DNA methylating (K562 cells):904 μg/mL|DNA methylating (HL6 cells cells):11.7 μg/mL
• In Vivo:
  METHODS: Streptozocin (40 mg/kg in the 50 mM sodium citrate buffer (pH 4.5), ready to use) was administered intraperitoneally to C57BL/6 or CD-1 male mice once daily for five days. Normal food and 10% sucrose water were provided during the administration period, and 10% sucrose water was replaced with normal water on the sixth day. RESULTS: Repeated low doses of Streptozocin induced type 1 diabetes in mice. METHODS: Streptozocin (200 mg/kg in the 50 mM sodium citrate buffer (pH 4.5), ready to use) was administered to C57BL/6 or CD-1 male mice by a single intraperitoneal injection. Normal food and 10% sucrose water were provided after administration, and 10% sucrose water was replaced with normal water on the third day. RESULTS: A single high dose of Streptozocin induced type 1 diabetes in mice.
• In Vitro:
  METHODS: Rat β-insulinoma cells Rin-5F were treated with Streptozocin (1-10 mM) for 2-48 h. Cell viability was measured using MTT assay. RESULTS: Maximum inhibition (60-70%) was observed in cells treated with 10 mM Streptozocin for 24 h and 48 h. The cells were treated with Streptozocin (1-10 mM) for 2-48 h, and cell viability was measured by MTT assay. METHODS: Neural stem cells were treated with Streptozocin (2.5 mM) for 2 days and gene expression was detected using RT-qPCR. RESULTS: Streptozocin significantly reduced the relative expression level of GLUT3 mRNA by 46.4%, and did not affect the relative expression level of IR and GLUT1.
• Cell Research:
  Streptozocin (STZ) stock solutions of 50 mg/mL in distilled Water (dWater) are freshly prepared for each experiment. Human and murine cell lines are cultured in triplicate in 96-well plates at a density of 2×104 cells/well in the absence (untreated control) or presence of various concentrations of ALX (20-3000 μg/mL) or STZ (1-3000 μg/mL) for 48 h at 37°C under a humidified atmosphere containing 5% CO2. Cells incubated in complete media including dWater in a final concentration of 0.1% served as control for solvent toxicity and cells incubated in complete medium are used as a control for the experiments. The effects of the tested drugs on tumor cell growth or viability are determined employing the MTT assay in accordance with the manufacturer's instructions. The IC50values (drug concentration that induces 50% inhibition of the cell growth) are calculated using the GraphPad Prism 4 program.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture,store at low temperature,store under nitrogen | Powder: -20°C for 3 years | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

U 9889, U9889, U-9889, RNASynthesis, RNA Synthesis, STZ, Streptozocin, Streptozotocin, Inhibitor, inhibit, NSC 85998, NSC85998, NSC-85998, DNA/RNA Synthesis, DNAAlkylator, DNAAlkylation, DNA Synthesis, DNASynthesis, DNA Alkylator, DNA alkylator, DNA Alkylation, DNA Alkylator/Crosslinker, Crosslinker, Autophagy, Bacterial, Antibiotic

Compound Identifiers

PubChem CID

5300

VI Sevastianov, AS Ponomareva, NV Baranova A Tissue-Engineered Construct Based on a Decellularized Scaffold and the Islets of Langerhans: A Streptozotocin-Induced Diabetic Model Life, (2024)

PubMed:

N. V. Baranova et al. Impact of pancreatic cell-engineered constructs on the islet apparatus in recipient rats with type I diabetes mellitus researchgate.net, (2025)

PubMed: